BioSpace News Archive

Acasti Pharma Inc. announced its operating and financial results for the third quarter of fiscal 2021 ended December 31, 2020.

Transitional Pass Through Payment (TPT) Facilitates Patient Access to New and Innovative Products That Have Shown Substantial Clinical Improvement

Evotec SE announced that the Company has entered into an integrated multi-target drug discovery agreement with biotech venture creation firm Related Sciences to generate multiple drug development candidates, biomarkers, and IND filings over a multi-year period.

Health Canada has approved Bactiguard’s urinary catheter with temperature sensor for infection prevention through an Interim Order.

Aesthetic Medical International Holdings Group Limited, a leading provider of aesthetic medical services in China, and Forbes China have jointly released the Chinese Aesthetic Treatment Industry White Paper 2020, the first white paper on the aesthetic treatment industry in China.

InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by carotid artery disease, announced the appointment of Chris Metzger, M.D., system chair of clinical research at Ballad Health System in Eastern Tennessee as the principal investigator for its planned FDA registration trial for CGuard EPS.

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced the publication of a study in the journal Nature Medicine that used NanoString’s GeoMx® Digital Spatial Profiler and the new Whole Transcriptome Atlas to profile sarcoma tissue.

Applied UV, Inc. announced it has closed on the acquisition by its wholly-owned subsidiary, SteriLumen, Inc., of substantially all of the assets of Akida Holdings LLC, including all of the rights to manufacture and sell the Airocide® System of patented, air disinfection and purification technologies, for 1.375 million common shares of Applied UV stock and $901,274.96 in cash.

Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that Triferic AVNU (ferric pyrophosphate citrate injection), the intravenous (IV) formulation of Triferic, is now available to patients in the United States.

Microbix Biosystems Inc., a life sciences innovator and exporter, is pleased to announce material first sales of its viral transport medium that supports Canadian RT-PCR testing for the virus causing COVID-19 disease.